Literature DB >> 11302816

In vitro antifungal activity of KP-103, a novel triazole derivative, and its therapeutic efficacy against experimental plantar tinea pedis and cutaneous candidiasis in guinea pigs.

Y Tatsumi1, M Yokoo, T Arika, H Yamaguchi.   

Abstract

The in vitro activity of KP-103, a novel triazole derivative, against pathogenic fungi that cause dermatomycoses and its therapeutic efficacy against plantar tinea pedis and cutaneous candidiasis in guinea pigs were investigated. MICs were determined by a broth microdilution method with morpholinepropanesulfonic acid-buffered RPMI 1640 medium for Candida species and with Sabouraud dextrose broth for dermatophytes and by an agar dilution method with medium C for Malassezia furfur. KP-103 was the most active of all the drugs tested against Candida albicans (geometric mean [GM] MIC, 0.002 microg/ml), other Candida species including Candida parapsilosis and Candida glabrata (GM MICs, 0.0039 to 0.0442 microg/ml), and M. furfur (GM MIC, 0.025 microg/ml). KP-103 (1% solution) was highly effective as a treatment for guinea pigs with cutaneous candidiasis and achieved mycological eradication in 8 of the 10 infected animals, whereas none of the imidazoles tested (1% solutions) was effective in even reducing the levels of the infecting fungi. KP-103 was as active as clotrimazole and neticonazole but was less active than lanoconazole and butenafine against Trichophyton rubrum (MIC at which 80% of isolates are inhibited [MIC(80)], 0.125 microg/ml) and Trichophyton mentagrophytes (MIC(80), 0.25 microg/ml). However, KP-103 (1% solution) exerted therapeutic efficacy superior to that of neticonazole and comparable to those of lanoconazole and butenafine, yielding negative cultures for all samples from guinea pigs with plantar tinea pedis tested. This suggests that KP-103 has better pharmacokinetic properties in skin tissue than the reference drugs. Because the in vitro activity of KP-103, unlike those of the reference drugs, against T. mentagrophytes was not affected by hair as a keratinic substance, its excellent therapeutic efficacy seems to be attributable to good retention of its antifungal activity in skin tissue, in addition to its potency.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11302816      PMCID: PMC90494          DOI: 10.1128/AAC.45.5.1493-1499.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  In vitro and in vivo antidermatophyte activities of NND-502, a novel optically active imidazole antimycotic agent.

Authors:  Y Niwano; N Kuzuhara; H Kodama; M Yoshida; T Miyazaki; H Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 2.  Pharmacokinetics of antimycotics with emphasis on local treatment.

Authors:  U Täuber
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

Review 3.  Bifonazole. A review of its antimicrobial activity and therapeutic use in superficial mycoses.

Authors:  T E Lackner; S P Clissold
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

Review 4.  Econazole: a review of its antifungal activity and therapeutic efficacy.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-09       Impact factor: 9.546

5.  Synthesis and antifungal activities of (2R,3R)-2-aryl-1-azolyl-3-(substituted amino)-2-butanol derivatives as topical antifungal agents.

Authors:  H Ogura; H Kobayashi; K Nagai; T Nishida; T Naito; Y Tatsumi; M Yokoo; T Arika
Journal:  Chem Pharm Bull (Tokyo)       Date:  1999-10       Impact factor: 1.645

6.  Laboratory assessment of the antimycotic drug clotrimazole.

Authors:  R J Holt; R L Newman
Journal:  J Clin Pathol       Date:  1972-12       Impact factor: 3.411

7.  Antagonistic action of lipid components of membranes from Candida albicans and various other lipids on two imidazole antimycotics, clotrimazole and miconazole.

Authors:  H Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1977-07       Impact factor: 5.191

8.  Antifungal activity of the allylamine derivative terbinafine in vitro.

Authors:  G Petranyi; J G Meingassner; H Mieth
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

9.  Tinea versicolor and Pityrosporum orbiculare: mycological investigations, experimental infections and epidemiological surveys.

Authors:  J Faergemann
Journal:  Acta Derm Venereol Suppl (Stockh)       Date:  1979

10.  Oxiconazole, a new imidazole derivative. Evaluation of antifungal activity in vitro and in vivo.

Authors:  A Polak
Journal:  Arzneimittelforschung       Date:  1982
View more
  16 in total

1.  The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment.

Authors:  Keita Sugiura; Noriaki Sugimoto; Shinya Hosaka; Maria Katafuchi-Nagashima; Yoshio Arakawa; Yoshiyuki Tatsumi; William Jo Siu; Radhakrishnan Pillai
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

Review 2.  Relevant Animal Models in Dermatophyte Research.

Authors:  Ludivine Cambier; Marie-Pierre Heinen; Bernard Mignon
Journal:  Mycopathologia       Date:  2016-10-11       Impact factor: 2.574

3.  Skin targeted lipid vesicles as novel nano-carrier of ketoconazole: characterization, in vitro and in vivo evaluation.

Authors:  Fang Guo; Jinping Wang; Man Ma; Fengping Tan; Nan Li
Journal:  J Mater Sci Mater Med       Date:  2015-04-01       Impact factor: 3.896

4.  In Vitro Activities of Luliconazole, Lanoconazole, and Efinaconazole Compared with Those of Five Antifungal Drugs against Melanized Fungi and Relatives.

Authors:  Gholam Reza Shokoohi; Hamid Badali; Hossein Mirhendi; Saham Ansari; Ali Rezaei-Matehkolaei; Bahram Ahmadi; Afsane Vaezi; Mohamed Mahdi Alshahni; Koichi Makimura
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

5.  Therapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine.

Authors:  Yoshiyuki Tatsumi; Mamoru Yokoo; Hisato Senda; Kazuaki Kakehi
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

6.  In Vitro Antifungal Activity of Novel Triazole Efinaconazole and Five Comparators against Dermatophyte Isolates.

Authors:  Ali Rezaei-Matehkolaei; Sadegh Khodavaisy; Mohamad Mahdi Alshahni; Takashi Tamura; Kazuo Satoh; Mahdi Abastabar; Gholam Reza Shokoohi; Bahram Ahmadi; Mohammad Kord; Simin Taghipour; Koichi Makimura; Hamid Badali
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

7.  Mechanism of action of efinaconazole, a novel triazole antifungal agent.

Authors:  Yoshiyuki Tatsumi; Maria Nagashima; Toshiyuki Shibanushi; Atsushi Iwata; Yumi Kangawa; Fumie Inui; William J Jo Siu; Radhakrishnan Pillai; Yayoi Nishiyama
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

8.  Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis.

Authors:  William J Jo Siu; Yoshiyuki Tatsumi; Hisato Senda; Radhakrishnan Pillai; Takashi Nakamura; Daisuke Sone; Annette Fothergill
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

9.  Intracutaneous distributions of fluconazole, itraconazole, and griseofulvin in Guinea pigs and binding to human stratum corneum.

Authors:  Satoshi Sobue; Kaneo Sekiguchi; Toshitaka Nabeshima
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

10.  Efinaconazole: first global approval.

Authors:  Trina Patel; Sohita Dhillon
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.